Omalizumab

Drug Profile

Omalizumab

Alternative Names: Anti-IgE monoclonal antibody E25; E 25; Humanised anti-IgE MAb; IgE 025; Monoclonal antibody E25; Olizumab; Recombinant human monoclonal antibody E25; rhuMAb 25; rhuMAb E25; Xolair

Latest Information Update: 18 Jul 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Genentech; Novartis
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic asthma; Urticaria
  • Phase II/III Mastocytosis
  • Phase II Nephritis
  • No development reported Peanut hypersensitivity

Most Recent Events

  • 22 Jun 2017 Novartis completes a phase-II/III trial in Mastocytosis in Australia (SC) (ACTRN12613001096741)
  • 01 Apr 2017 Novartis terminates the phase II CUTEX trial in Urticaria (Treatment-experienced) in Germany as the study met its primary endpoint at the planned interim analysis
  • 27 Jan 2017 Novartis has patent protection for omalizumab in USA, Europe and Japan (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top